Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1947 1
1950 4
1951 9
1952 9
1953 13
1954 3
1955 4
1956 9
1957 9
1958 15
1959 29
1960 49
1961 55
1962 72
1963 87
1964 98
1965 42
1966 45
1967 53
1968 91
1969 93
1970 87
1971 82
1972 105
1973 103
1974 134
1975 116
1976 178
1977 138
1978 228
1979 267
1980 216
1981 235
1982 260
1983 325
1984 264
1985 262
1986 309
1987 222
1988 201
1989 290
1990 154
1991 132
1992 212
1993 129
1994 123
1995 104
1996 133
1997 134
1998 117
1999 117
2000 79
2001 93
2002 89
2003 81
2004 88
2005 76
2006 118
2007 89
2008 123
2009 108
2010 140
2011 125
2012 197
2013 330
2014 332
2015 315
2016 275
2017 314
2018 267
2019 204
2020 43
Text availability
Article attribute
Article type
Publication date

Search Results

9,143 results
Results by year
Filters applied: . Clear all
Page 1
Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer.
Hussain M, Fizazi K, Saad F, Rathenborg P, Shore N, Ferreira U, Ivashchenko P, Demirhan E, Modelska K, Phung D, Krivoshik A, Sternberg CN. Hussain M, et al. N Engl J Med. 2018 Jun 28;378(26):2465-2474. doi: 10.1056/NEJMoa1800536. N Engl J Med. 2018. PMID: 29949494 Free article. Clinical Trial.
Managing Nonmetastatic Castration-resistant Prostate Cancer.
Mateo J, Fizazi K, Gillessen S, Heidenreich A, Perez-Lopez R, Oyen WJG, Shore N, Smith M, Sweeney C, Tombal B, Tomlins SA, de Bono JS. Mateo J, et al. Eur Urol. 2019 Feb;75(2):285-293. doi: 10.1016/j.eururo.2018.07.035. Epub 2018 Aug 14. Eur Urol. 2019. PMID: 30119985 Free article. Review.
Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial.
Boevé LMS, Hulshof MCCM, Vis AN, Zwinderman AH, Twisk JWR, Witjes WPJ, Delaere KPJ, Moorselaar RJAV, Verhagen PCMS, van Andel G. Boevé LMS, et al. Eur Urol. 2019 Mar;75(3):410-418. doi: 10.1016/j.eururo.2018.09.008. Epub 2018 Sep 25. Eur Urol. 2019. PMID: 30266309 Clinical Trial.
[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study.
Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T, Iravani A, Kong G, Ravi Kumar A, Murphy DG, Eu P, Jackson P, Scalzo M, Williams SG, Sandhu S. Hofman MS, et al. Lancet Oncol. 2018 Jun;19(6):825-833. doi: 10.1016/S1470-2045(18)30198-0. Epub 2018 May 8. Lancet Oncol. 2018. PMID: 29752180 Clinical Trial.
Pharmacotherapy.
Fineman SM, Khan DA, Dinakar C, Lang DM, Tilles SA. Fineman SM, et al. Ann Allergy Asthma Immunol. 2018 Jul;121(1):22-23. doi: 10.1016/j.anai.2018.05.008. Epub 2018 May 16. Ann Allergy Asthma Immunol. 2018. PMID: 29777743 No abstract available.
Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial.
Saad F, Cella D, Basch E, Hadaschik BA, Mainwaring PN, Oudard S, Graff JN, McQuarrie K, Li S, Hudgens S, Lawson J, Lopez-Gitlitz A, Yu MK, Smith MR, Small EJ. Saad F, et al. Lancet Oncol. 2018 Oct;19(10):1404-1416. doi: 10.1016/S1470-2045(18)30456-X. Epub 2018 Sep 10. Lancet Oncol. 2018. PMID: 30213449 Clinical Trial.
Recent advances in theranostics and challenges for the future.
Turner JH. Turner JH. Br J Radiol. 2018 Nov;91(1091):20170893. doi: 10.1259/bjr.20170893. Epub 2018 Mar 29. Br J Radiol. 2018. PMID: 29565650 Free PMC article. Review.
Response.
Briollais L, Bristow RG, Boutros PC; PRACTICAL consortium, Zlotta AR. Briollais L, et al. J Natl Cancer Inst. 2017 Dec 1;109(12). doi: 10.1093/jnci/djx122. J Natl Cancer Inst. 2017. PMID: 30053077 No abstract available.
9,143 results
Jump to page
Feedback